Pioneering Massive Directed
Evolution to Unlock Infinite
Potential of Cell Therapy
Pioneering Directed Evolution of Immune Cells
To revolutionize cell therapy, we develop proprietary next-generation technologies that opens near-infinite
possibilities of cell therapy by:
We welcome you to join our mission of treating cancer with innovative science.
Get in touch today to learn more about the Cellinfinity Bio story.
Harness the power of natural selection to identify most robust genetic modifications that optimize immune cells' potency, persistence, infiltration
Engineer & create potent immune cells with technologies that are robust, reproducible, and highly efficient.
Create Diverse Pool
Generate large collection/library
of thousands of therapeutic
immune cells, each with unique
gain-of-function and/or loss-of-function gene modification.
We use directed evolution experiments to identify genetic modifications and CAR constructs that substantially improve engineered immune cell function against cancer.
These discoveries allow development of first-in-class (with proprietary gene modifications and unique targets/CARs) and best-in-class (with proprietary modifications and optimized CARs) products.
Our pipeline consists of genetically engineered T cell, NK cell and other immune cells that have potent activity against multiple malignancies including solid tumors.
Cellinfinity Bio is led by seasoned industry veterans, scientists, and business leaders.
Premal Patel, MD/PHD
Chief Executive Officer
Over 15 years of oncology drug development
Former Chief Medical Officer at Lyell Immunopharma and at eFFECTOR Therapeutics
SVP Juno Therapeutics (Head, Early Clinical Development)
VP Pfizer (Head of Immuno-Onc Early Clinical Dev, allogeneic CARTs licensed to Allogene)
Sr Director Genentech, Research and Early Clinical Development
Philip Kong, PHD
Chief Operating Officer
Former founder and CSO of Statera Therapeutics
7+ years of immunology R&D
4+ years of life sciences investment at hedge funds
Former strategy consultant at Flagship Pioneering, Naveos Biopharma, and Nucleate Bio
Sidi Chen, PHD
Founder of Cellinfinity Bio
Associate Professor at Yale University and group leader at Yale University
Prolific publication and invention records in gene editing and immunotherapy
Margo Roberts, PHD
Chief Scientific Advisor
Superb track records in cell therapy
Former chief scientific officer (CSO) at Lyell Immunopharma and Kite Pharma. Led multiple cell therapy programs to clinic.
Endpoints News’ Top 20 Women Leaders in Biopharma 2020.
Greg Naeve, PHD
Chief Business Officer
Biotech/Pharma Executive and Entrepreneur with strong BD records and expertise
President, Parallax Strategic Advisors, Chief Business Officer, Bellicum Pharmaceuticals
Prior R&D Lead, ImmunoOncology & Cell Therapy, Pfizer
Michael Green, MBA
Chief Financial Officer
25+ years of financial & operational executive leadership roles within pharma, biotech, medical device, service, technology, and manufacturing industries
Held CFO level roles for pre-revenue start-ups, middle market companies, and large public entities
Expertise in turnaround, cost reduction, capital raise, debt structuring, M&A transactions, financial modeling, accounting, cash management, and strategic planning
Dai, X., Park, J.J., Du, Y. et al. Massively parallel knock-in engineering of human T cells. (2023).
Nature Biotechnology 2023. https://doi.org/10.1038/s41587-022-01639-x PDF
Ye, L., Park, J. J., Peng, L., Yang, Q., Chow, R. D., Dong, M. B., … & Chen, S. (2022).
A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy.
Cell Metabolism 2022. doi: 10.1016/j.cmet.2022.02.009 PDF
Dai X*, Park JJ*, Du Y, Kim HR, Wang G, Errami Y, Chen S. One-step generation of modular CAR-T with AAV-Cpf1.
Nature Methods 2019. doi: 10.1038/s41592-019-0329. PDF
Venkata 'Sekhar' Boddupalli
January 26, 2023
Cellinfinity Bio Announces Publication and Licensing of Key Technology for Directed Evolution of Cells That Allows for More Effective Adoptive Cell Therapy
“I’m delighted to be a part of Cellinfinity Bio's exciting and innovative approach to cell therapy,
and I look forward to working together on the development of game-changing immunotherapies
Chief Scientific Advisor
Former Chief Scientific Officer, Lyell Immunopharma & Kite Pharma
All interested applicants should submit their resume and cover letter to firstname.lastname@example.org
Note to recruitment agencies: Cellinfinity Bio does not accept unsolicited resumes from recruitment agencies. Cellinfinity Bio is not responsible for any fees related to resumes that have been distributed without agreement.
520 West Campus Drive, West Haven, CT 06516
930 Brittan Ave, San Carlos, CA 94070